Center for Medical Image Science and Visualization (CMIV), Linköping University, SE-58185, Linköping, Sweden.
Eur Radiol. 2012 Mar;22(3):642-53. doi: 10.1007/s00330-011-2302-4. Epub 2011 Oct 9.
To develop and evaluate a procedure for quantifying the hepatocyte-specific uptake of Gd-BOPTA and Gd-EOB-DTPA using dynamic contrast-enhanced (DCE) MRI.
Ten healthy volunteers were prospectively recruited and 21 patients with suspected hepatobiliary disease were retrospectively evaluated. All subjects were examined with DCE-MRI using 0.025 mmol/kg of Gd-EOB-DTPA. The healthy volunteers underwent an additional examination using 0.05 mmol/kg of Gd-BOPTA. The signal intensities (SI) of liver and spleen parenchyma were obtained from unenhanced and enhanced acquisitions. Using pharmacokinetic models of the liver and spleen, and an SI rescaling procedure, a hepatic uptake rate, K (Hep), estimate was derived. The K (Hep) values for Gd-EOB-DTPA were then studied in relation to those for Gd-BOPTA and to a clinical classification of the patient's hepatobiliary dysfunction.
K (Hep) estimated using Gd-EOB-DTPA showed a significant Pearson correlation with K (Hep) estimated using Gd-BOPTA (r = 0.64; P < 0.05) in healthy subjects. Patients with impaired hepatobiliary function had significantly lower K (Hep) than patients with normal hepatobiliary function (K (Hep) = 0.09 ± 0.05 min(-1) versus K (Hep) = 0.24 ± 0.10 min(-1); P < 0.01).
A new procedure for quantifying the hepatocyte-specific uptake of T (1)-enhancing contrast agent was demonstrated and used to show that impaired hepatobiliary function severely influences the hepatic uptake of Gd-EOB-DTPA.
• The liver uptake of contrast agents may be measured with standard clinical MRI. • Calculation of liver contrast agent uptake is improved by considering splenic uptake. • Liver function affects the uptake of the liver-specific contrast agent Gd-EOB-DTPA. • Hepatic uptake of two contrast agents (Gd-EOB-DTPA, Gd-BOPTA) is correlated in healthy individuals. • This method can be useful for determining liver function, e.g. before hepatic surgery.
开发和评估一种使用动态对比增强（DCE）MRI 量化 Gd-BOPTA 和 Gd-EOB-DTPA 肝特异性摄取的方法。
前瞻性招募 10 名健康志愿者和 21 名疑似肝胆疾病患者进行回顾性评估。所有受试者均使用 0.025mmol/kg 的 Gd-EOB-DTPA 进行 DCE-MRI 检查。健康志愿者还额外接受了 0.05mmol/kg 的 Gd-BOPTA 检查。从未增强和增强采集获得肝脏和脾脏实质的信号强度（SI）。使用肝脏和脾脏的药代动力学模型以及 SI 缩放过程，得出肝摄取率 K（Hep）的估计值。然后研究 Gd-EOB-DTPA 的 K（Hep）值与 Gd-BOPTA 的 K（Hep）值以及患者肝胆功能障碍的临床分类之间的关系。
在健康受试者中，使用 Gd-EOB-DTPA 估计的 K（Hep）与使用 Gd-BOPTA 估计的 K（Hep）呈显著的 Pearson 相关关系（r=0.64；P<0.05）。肝胆功能障碍患者的 K（Hep）明显低于肝胆功能正常的患者（K（Hep）=0.09±0.05min-1 与 K（Hep）=0.24±0.10min-1；P<0.01）。
本研究证明了一种量化 T1 增强型对比剂肝特异性摄取的新方法，并用于表明肝胆功能障碍严重影响 Gd-EOB-DTPA 的肝摄取。
可使用标准临床 MRI 测量对比剂的肝脏摄取。
通过考虑脾脏摄取，计算肝对比剂摄取的准确性得到提高。
肝功能影响肝特异性对比剂 Gd-EOB-DTPA 的摄取。
两种对比剂（Gd-EOB-DTPA、Gd-BOPTA）在健康个体中的摄取呈正相关。
该方法可用于确定肝功能，例如在肝手术前。
